Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 95 | 16 | 79 |
| Samples | 94 | 16 | 78 |
| Peptides | 63 | 11 | 54 |
Function
IL19 · Interleukin 19
The protein encoded by this gene is a cytokine that belongs to the IL10 cytokine subfamily. This cytokine is found to be preferentially expressed in monocytes. It can bind the IL20 receptor complex and lead to the activation of the signal transducer and activator of transcription 3 (STAT3). A similar cytokine in mouse is reported to up-regulate the expression of IL6 and TNF-alpha and induce apoptosis, which suggests a role of this cytokine in inflammatory responses. Alternatively spliced transcript variants encoding the distinct isoforms have been described. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 59 amino-acid changes on canonical ENST00000270218 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in IL19 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in IL19 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Bladder Carcinoma | 2/58 3% | 4/956 0% |
| Colorectal Carcinoma | 2/143 1% | 17/3239 1% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 4/1390 0% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
| Mesothelioma | 0/62 0% | 1/165 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 2/810 0% |
| Melanoma | 0/210 0% | 7/1899 0% |
| Gastric Carcinoma | 0/74 0% | 6/1809 0% |
| Endometrial Carcinoma | 0/42 0% | 2/612 0% |
| Ovarian Carcinoma | 0/109 0% | 3/998 0% |
| Other Solid Cancers | 1/94 1% | 3/1515 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 4/1592 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 5/2550 0% |
| Hepatocellular Carcinoma | 1/46 2% | 2/2210 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
| Head and Neck Carcinoma | 0/85 0% | 2/1574 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
| Glioma | 0/52 0% | 2/2127 0% |
| Pancreatic Carcinoma | 0/89 0% | 1/1611 0% |
| Kidney Carcinoma | 1/85 1% | 0/1862 0% |
| Other Blood Cancers | 0/61 0% | 1/2725 0% |
| B-Lymphoblastic Leukemia | 1/55 2% | 0/2640 0% |
| Breast Carcinoma | 0/144 0% | 1/3264 0% |
Mutation Distribution
Where IL19 is mutated · all tissues, split by cell line vs tissue
How many mutations in IL19 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 15 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 95 mutations in IL19
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|